AN2 Therapeutics, a biopharma company focused on small molecules, plans to lay off approximately half of its 41 employees across research, manufacturing, clinical operations regulatory and quality.
 
Eric Easom, AN2 co-founder, chairman, president and CEO, said, “In the near-term, we plan to accelerate our R&D efforts on our boron chemistry platform where we believe we have several promising programs in infectious diseases and oncology.”
 
As part of an effort to extend the company’s operating capital and execute its ongoing strategy. The restructuring will result in charges of approximately $2 – $3 million, including severance and other related expenses.
 
Scheduled to be complete by the end of 2024, the layoffs include company’s chief medical officer Paul Eckburg, who will provide consulting services to the company during a transition period.
 
The focus shift follows discontinuation of its study of EBO-301, which evaluated epetraborole along with an optimized background regimen (OBR) in treatment-refractory MAC lung disease. While the study met its primary objective of demonstrating potential validation of a novel patient-reported outcome tool and a higher PRO-based clinical response rate in the epetraborole plus OBR arm vs. placebo plus OBR, a key secondary endpoint, showed similarity between treatment arms.